Hear Dr. Gerry Kenna, Pharmaceutical Director, Safer Medicines Trust, will discuss pragmatic recommendations by the International Transporter Consortium (ITC) on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk.
- Review conventional and emerging in vitro models
- Practical advice on conducting BSEP inhibition studies
- Recommendations for an IND submission strategy
Dr. Gerry Kenna
Safer Medicines Trust
Dr. Gerry Kenna is Pharmaceutical Director of Safer Medicines Trust, a drug safety consultant and Vice President of the Board of Trustees of the Evidence Based Toxicology Collaboration. His work is focused on developing and implementing novel, human biology-based methods that can improve human drug safety evaluation. Previously he was a toxicologist in the pharmaceutical and agrochemical industries for 15 years, having led academic research teams that explored mechanisms underlying serious human adverse drug reactions for 19 years. Dr. Kenna received B.Sc. and Ph.D. degrees in biochemistry from the Universities of Leeds and London, respectively.